Anti -RPS6KA3 (ISPK1, MAPKAPK1B, RSK2, Ribosomal protein S6 kinase alpha-3, 90kD ribosomal protein S6 kinase 2, Insulin-stimulated protein kinase 1, MAP kinase-activated protein kinase 1b, Ribosomal S6 kinase 2, pp90RSK2)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: X; NC_000023.10 (20168029..20285523, complement). Location: Xp22.2-p22.1

Polyclonal

Rabbit

Recognizes rat RPS6KA3/RSK2. Species Crossreactivity: Bovine, canine, chicken, human, mouse, rat.

Affinity Purified
Purified by immunoaffinity chromatography

Supplied as a liquid in HEPES (pH 7.5), 150mM NaCl, 100ug per ml BSA, 50% glycerol.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-RPS6KA3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

RSK2, an RSK serine/threonine kinase, has been implicated in Coffin-Lowry syndrome, a disease characterized by cognitive impairment, characteristic facial and digital findings and skeletal anomalies.

Antibodies; Abs to Protein Kinases

Western Blot (WB), Immunohistochemistry (IHC)

Suitable for use in Western Blot and Immunohistochemistry.
Dilution: Western Blot: 1:1000
Immunohistochemistry (Paraffin): 1:100

83,736 Da[Similar Products]

ribosomal protein S6 kinase, 90kDa, polypeptide 3

ribosomal protein S6 kinase alpha-3; RSK-2; p90-RSK 3; MAPKAPK-1b; S6K-alpha-3; MAPKAP kinase 1b; ribosomal S6 kinase 2; MAPK-activated protein kinase 1b; insulin-stimulated protein kinase 1; MAP kinase-activated protein kinase 1b

Ribosomal protein S6 kinase alpha-3

ISPK1; MAPKAPK1B; RSK2; S6K-alpha-3; p90-RSK 3; p90RSK3; ISPK-1; MAPK-activated protein kinase 1b; MAPKAP kinase 1b; MAPKAPK-1b; RSK-2??[Similar Products]

KS6A3_HUMAN

This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome (CLS). [provided by RefSeq, Jul 2008]

Function: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1. Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.15 Ref.16

Catalytic activity: ATP + a protein = ADP + a phosphoprotein.

Cofactor: Magnesium

By similarity.

Enzyme regulation: Upon extracellular signal or mitogen stimulation, phosphorylated at Thr-577 in the C-terminal kinase domain (CTKD) by MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates Ser-386, allowing binding of PDPK1, which in turn phosphorylates Ser-227 in the N-terminal kinase domain (NTDK) leading to the full activation of the protein and subsequent phosphorylation of the substrates by the NTKD.

Subunit structure: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in quiescent cells. Transiently dissociates following mitogenic stimulation

By similarity. Interacts with NFATC4, ETV1/ER81 and FGFR1. Ref.14

Subcellular location: Nucleus

By similarity. Cytoplasm

By similarity.

Tissue specificity: Expressed in many tissues, highest levels in skeletal muscle.

Post-translational modification: Activated by phosphorylation at Ser-227 by PDPK1. Autophosphorylated on Ser-386, as part of the activation process. May be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and MAPK3/ERK1. Can also be activated via phosphorylation at Ser-386 by MAPKAPK2.N-terminal myristoylation results in an activated kinase in the absence of added growth factors.

Involvement in disease: Coffin-Lowry syndrome (CLS) [MIM:303600]: A X-linked mental retardation associated with facial and digital dysmorphisms, progressive skeletal malformations, growth retardation, hearing deficit and paroxysmal movement disorders.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.26 Ref.27 Ref.28 Ref.29 Ref.31 Ref.32Mental retardation, X-linked 19 (MRX19) [MIM:300844]: A non-syndromic form of mild to moderate mental retardation. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. In contrast to syndromic or specific X-linked mental retardation which also present with associated physical, neurological and/or psychiatric manifestations, intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.30 Ref.33

Sequence similarities: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily.Contains 1 AGC-kinase C-terminal domain.Contains 2 protein kinase domains.

Sequence caution: The sequence BAD92170.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.